Artificial intelligence in pulmonary medicine: computer vision, predictive model and COVID-19

Ethical trade-offs in AI for mental health

It is expected that machine learning algorithms will enable better diagnosis, prognosis, and treatment in psychiatry. A central argument for deploying algorithmic methods in clinical decision-making in psychiatry is that they may enable not only faster and more accurate clinical judgments but also that they may provide a more objective foundation for clinical decisions. This article argues that the outputs of algorithms are never objective in the sense of being unaffected by human values and possibly biased choices. And it suggests that the best way to approach this is to ensure awareness of and transparency about the ethical trade-offs that must be made when developing an algorithm for mental health.

Artificial intelligence in respiratory care: Current scenario and future perspective

BACKGROUND

This narrative review aims to explore the current state and future perspective of artificial intelligence (AI) in respiratory care. The objective is to provide insights into the potential impact of AI in this field.

METHODS

A comprehensive analysis of relevant literature and research studies was conducted to examine the applications of AI in respiratory care and identify areas of advancement. The analysis included studies on remote monitoring, early detection, smart ventilation systems, and collaborative decision-making.

RESULTS

The obtained results highlight the transformative potential of AI in respiratory care. AI algorithms have shown promising capabilities in enabling tailored treatment plans based on patient-specific data. Remote monitoring using AI-powered devices allows for real-time feedback to health-care providers, enhancing patient care. AI algorithms have also demonstrated the ability to detect respiratory conditions at an early stage, leading to timely interventions and improved outcomes. Moreover, AI can optimize mechanical ventilation through continuous monitoring, enhancing patient comfort and reducing complications. Collaborative AI systems have the potential to augment the expertise of health-care professionals, leading to more accurate diagnoses and effective treatment strategies.

CONCLUSION

By improving diagnosis, AI has the potential to revolutionize respiratory care, treatment planning, and patient monitoring. While challenges and ethical considerations remain, the transformative impact of AI in this domain cannot be overstated. By leveraging the advancements and insights from this narrative review, health-care professionals and researchers can continue to harness the power of AI to improve patient outcomes and enhance respiratory care practices.

IMPROVEMENTS

Based on the findings, future research should focus on refining AI algorithms to enhance their accuracy, reliability, and interpretability. In addition, attention should be given to addressing ethical considerations, ensuring data privacy, and establishing regulatory frameworks to govern the responsible implementation of AI in respiratory care.

Analysis of Validation Performance of a Machine Learning Classifier in Interstitial Lung Disease Cases Without Definite or Probable Usual Interstitial Pneumonia Pattern on CT Using Clinical and Pathology-Supported Diagnostic Labels

We previously validated Fibresolve, a machine learning classifier system that non-invasively predicts idiopathic pulmonary fibrosis (IPF) diagnosis. The system incorporates an automated deep learning algorithm that analyzes chest computed tomography (CT) imaging to assess for features associated with idiopathic pulmonary fibrosis. Here, we assess performance in assessment of patterns beyond those that are characteristic features of usual interstitial pneumonia (UIP) pattern. The machine learning classifier was previously developed and validated using standard training, validation, and test sets, with clinical plus pathologically determined ground truth. The multi-site 295-patient validation dataset was used for focused subgroup analysis in this investigation to evaluate the classifier's performance range in cases with and without radiologic UIP and probable UIP designations. Radiologic assessment of specific features for UIP including the presence and distribution of reticulation, ground glass, bronchiectasis, and honeycombing was used for assignment of radiologic pattern. Output from the classifier was assessed within various UIP subgroups. The machine learning classifier was able to classify cases not meeting the criteria for UIP or probable UIP as IPF with estimated sensitivity of 56-65% and estimated specificity of 92-94%. Example cases demonstrated non-basilar-predominant as well as ground glass patterns that were indeterminate for UIP by subjective imaging criteria but for which the classifier system was able to correctly identify the case as IPF as confirmed by multidisciplinary discussion generally inclusive of histopathology. The machine learning classifier Fibresolve may be helpful in the diagnosis of IPF in cases without radiological UIP and probable UIP patterns.

Advancements in cardiac structures segmentation: a comprehensive systematic review of deep learning in CT imaging

Background

Segmentation of cardiac structures is an important step in evaluation of the heart on imaging. There has been growing interest in how artificial intelligence (AI) methods-particularly deep learning (DL)-can be used to automate this process. Existing AI approaches to cardiac segmentation have mostly focused on cardiac MRI. This systematic review aimed to appraise the performance and quality of supervised DL tools for the segmentation of cardiac structures on CT.

Methods

Embase and Medline databases were searched to identify related studies from January 1, 2013 to December 4, 2023. Original research studies published in peer-reviewed journals after January 1, 2013 were eligible for inclusion if they presented supervised DL-based tools for the segmentation of cardiac structures and non-coronary great vessels on CT. The data extracted from eligible studies included information about cardiac structure(s) being segmented, study location, DL architectures and reported performance metrics such as the Dice similarity coefficient (DSC). The quality of the included studies was assessed using the Checklist for Artificial Intelligence in Medical Imaging (CLAIM).

Results

18 studies published after 2020 were included. The DSC scores median achieved for the most commonly segmented structures were left atrium (0.88, IQR 0.83-0.91), left ventricle (0.91, IQR 0.89-0.94), left ventricle myocardium (0.83, IQR 0.82-0.92), right atrium (0.88, IQR 0.83-0.90), right ventricle (0.91, IQR 0.85-0.92), and pulmonary artery (0.92, IQR 0.87-0.93). Compliance of studies with CLAIM was variable. In particular, only 58% of studies showed compliance with dataset description criteria and most of the studies did not test or validate their models on external data (81%).

Conclusion

Supervised DL has been applied to the segmentation of various cardiac structures on CT. Most showed similar performance as measured by DSC values. Existing studies have been limited by the size and nature of the training datasets, inconsistent descriptions of ground truth annotations and lack of testing in external data or clinical settings.

Systematic Review Registration

[www.crd.york.ac.uk/prospero/], PROSPERO [CRD42023431113].

Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19

OBJECTIVES

COVID-19 pandemic seems to be under control. However, despite the vaccines, 5 to 10% of the patients with mild disease develop moderate to critical forms with potential lethal evolution. In addition to assess lung infection spread, chest CT helps to detect complications. Developing a prediction model to identify at-risk patients of worsening from mild COVID-19 combining simple clinical and biological parameters with qualitative or quantitative data using CT would be relevant to organizing optimal patient management.

METHODS

Four French hospitals were used for model training and internal validation. External validation was conducted in two independent hospitals. We used easy-to-obtain clinical (age, gender, smoking, symptoms' onset, cardiovascular comorbidities, diabetes, chronic respiratory diseases, immunosuppression) and biological parameters (lymphocytes, CRP) with qualitative or quantitative data (including radiomics) from the initial CT in mild COVID-19 patients.

RESULTS

Qualitative CT scan with clinical and biological parameters can predict which patients with an initial mild presentation would develop a moderate to critical form of COVID-19, with a c-index of 0.70 (95% CI 0.63; 0.77). CT scan quantification improved the performance of the prediction up to 0.73 (95% CI 0.67; 0.79) and radiomics up to 0.77 (95% CI 0.71; 0.83). Results were similar in both validation cohorts, considering CT scans with or without injection.

CONCLUSION

Adding CT scan quantification or radiomics to simple clinical and biological parameters can better predict which patients with an initial mild COVID-19 would worsen than qualitative analyses alone. This tool could help to the fair use of healthcare resources and to screen patients for potential new drugs to prevent a pejorative evolution of COVID-19.

CLINICAL TRIAL REGISTRATION

NCT04481620.

CLINICAL RELEVANCE STATEMENT

CT scan quantification or radiomics analysis is superior to qualitative analysis, when used with simple clinical and biological parameters, to determine which patients with an initial mild presentation of COVID-19 would worsen to a moderate to critical form.

KEY POINTS

• Qualitative CT scan analyses with simple clinical and biological parameters can predict which patients with an initial mild COVID-19 and respiratory symptoms would worsen with a c-index of 0.70. • Adding CT scan quantification improves the performance of the clinical prediction model to an AUC of 0.73. • Radiomics analyses slightly improve the performance of the model to a c-index of 0.77.

Imagistic Findings Using Artificial Intelligence in Vaccinated versus Unvaccinated SARS-CoV-2-Positive Patients Receiving In-Care Treatment at a Tertiary Lung Hospital

BACKGROUND

In December 2019 the World Health Organization announced that the widespread severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had become a global pandemic. The most affected organ by the novel virus is the lung, and imaging exploration of the thorax using computer tomography (CT) scanning and X-ray has had an important impact.

MATERIALS AND METHODS

We assessed the prevalence of lung lesions in vaccinated versus unvaccinated SARS-CoV-2 patients using an artificial intelligence (AI) platform provided by Medicai. The software analyzes the CT scans, performing the lung and lesion segmentation using a variant of the U-net convolutional network.

RESULTS

We conducted a cohort study at a tertiary lung hospital in which we included 186 patients: 107 (57.52%) male and 59 (42.47%) females, of which 157 (84.40%) were not vaccinated for SARS-CoV-2. Over five times more unvaccinated patients than vaccinated ones are admitted to the hospital and require imaging investigations. More than twice as many unvaccinated patients have more than 75% of the lungs affected. Patients in the age group 30-39 have had the most lung lesions at almost 69% of both lungs affected. Compared to vaccinated patients with comorbidities, unvaccinated patients with comorbidities had developed increased lung lesions by 5%.

CONCLUSION

The study revealed a higher percentage of lung lesions among unvaccinated SARS-CoV-2-positive patients admitted to The National Institute of Pulmonology "Marius Nasta" in Bucharest, Romania, underlining the importance of vaccination and also the usefulness of artificial intelligence in CT interpretation.

Clinical application of radiological AI for pulmonary nodule evaluation: Replicability and susceptibility to the population shift caused by the COVID-19 pandemic

PURPOSE

replicability and generalizability of medical AI are the recognized challenges that hinder a broad AI deployment in clinical practice. Pulmonary nodes detection and characterization based on chest CT images is one of the demanded use cases for automatization by means of AI, and multiple AI solutions addressing this task are becoming available. Here, we evaluated and compared the performance of several commercially available radiological AI with the same clinical task on the same external datasets acquired before and during the pandemic of COVID-19.

APPROACH

5 commercially available AI models for pulmonary nodule detection were tested on two external datasets labelled by experts according to the intended clinical task. Dataset1 was acquired before the pandemic and did not contain radiological signs of COVID-19; dataset2 was collected during the pandemic and did contain radiological signs of COVID-19. ROC-analysis was applied separately for the dataset1 and dataset2 to select probability thresholds for each dataset separately. AUROC, sensitivity and specificity metrics were used to assess and compare the results of AI performance.

RESULTS

Statistically significant differences in AUROC values were observed between the AI models for the dataset1. Whereas for the dataset2 the differences of AUROC values became statistically insignificant. Sensitivity and specificity differed statistically significantly between the AI models for the dataset1. This difference was insignificant for the dataset2 when we applied the probability threshold initially selected for the dataset1. An update of the probability threshold based on the dataset2 created statistically significant differences of sensitivity and specificity between AI models for the dataset2. For 3 out of 5 AI models, the update of the probability threshold was valuable to compensate for the degradation of AI model performances with the population shift caused by the pandemic.

CONCLUSIONS

Population shift in the data is able to deteriorate differences of AI models performance. Update of the probability threshold together with the population shift seems to be valuable to preserve AI models performance without retraining them.

Mediating effect of work stress in the relationship between fear of COVID-19 and nurses' organizational and professional turnover intentions

Nursing is one of the most stressful and high-risk professions. It is important to identify the psychological problems experienced by nurses during the COVID-19 pandemic and examine the relationship between these problems to devise measures that can properly address them. This study examined mediating effect of work stress in the relationship between fear of COVID-19 and nurses' organizational and professional turnover intentions. Using a cross-sectional research design, this study was conducted on 486 nurses working in seven hospitals in Turkey. The mean age of the participants was 35.24 ± 6.81 and 59.9 % of them were women. The Fear of COVID-19 Scale, the General Work Stress Scale, and the Turnover Intention Scale were used to collect data. A mediation model showed that fear of COVID-19 was positively associated with work stress and organizational and professional turnover intentions. The model also revealed that work stress was positively associated with organizational and professional turnover intentions. Furthermore, the results demonstrated that fear of COVID-19 did not only have a direct effect on organizational and professional turnover intentions but also had an indirect effect on it via increased work stress. Findings improve our understanding of the role of work stress in the relationship between fear of COVID-19 and organizational and professional turnover intentions. The findings are fruitful for tailoring and implementing intervention programs to reduce the adverse psychological impacts of COVID-19 on nurses.

A hybrid random forest deep learning classifier empowered edge cloud architecture for COVID-19 and pneumonia detection

COVID-19 is a global pandemic that mostly affects patients' respiratory systems, and the only way to protect oneself against the virus at present moment is to diagnose the illness, isolate the patient, and provide immunization. In the present situation, the testing used to predict COVID-19 is inefficient and results in more false positives. This difficulty can be solved by developing a remote medical decision support system that detects illness using CT scans or X-ray images with less manual interaction and is less prone to errors. The state-of-art techniques mainly used complex deep learning architectures which are not quite effective when deployed in resource-constrained edge devices. To overcome this problem, a multi-objective Modified Heat Transfer Search (MOMHTS) optimized hybrid Random Forest Deep learning (HRFDL) classifier is proposed in this paper. The MOMHTS algorithm mainly optimizes the deep learning model in the HRFDL architecture by optimizing the hyperparameters associated with it to support the resource-constrained edge devices. To evaluate the efficiency of this technique, extensive experimentation is conducted on two real-time datasets namely the COVID19 lung CT scan dataset and the Chest X-ray images (Pneumonia) datasets. The proposed methodology mainly offers increased speed for communication between the IoT devices and COVID-19 detection via the MOMHTS optimized HRFDL classifier is modified to support the resources which can only support minimal computation and handle minimum storage. The proposed methodology offers an accuracy of 99% for both the COVID19 lung CT scan dataset and the Chest X-ray images (Pneumonia) datasets with minimal computational time, cost, and storage. Based on the simulation outcomes, we can conclude that the proposed methodology is an appropriate fit for edge computing detection to identify the COVID19 and pneumonia with higher detection accuracy.

Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines?

Gene therapy enables the introduction of nucleic acids like DNA and RNA into host cells, and is expected to revolutionize the treatment of a wide range of diseases. This growth has been further accelerated by the discovery of CRISPR/Cas technology, which allows accurate genomic editing in a broad range of cells and organisms in vitro and in vivo. Despite many advances in gene delivery and the development of various viral and non-viral gene delivery vectors, the lack of highly efficient non-viral systems with low cellular toxicity remains a challenge. The application of cutting-edge technologies such as artificial intelligence (AI) has great potential to find new paradigms to solve this issue. Herein, we review AI and its major subfields including machine learning (ML), neural networks (NNs), expert systems, deep learning (DL), computer vision and robotics. We discuss the potential of AI-based models and algorithms in the design of targeted gene delivery vehicles capable of crossing extracellular and intracellular barriers by viral mimicry strategies. We finally discuss the role of AI in improving the function of CRISPR/Cas systems, developing novel nanobots, and mRNA vaccine carriers.

Identification of robust deep neural network models of longitudinal clinical measurements

Deep learning (DL) from electronic health records holds promise for disease prediction, but systematic methods for learning from simulated longitudinal clinical measurements have yet to be reported. We compared nine DL frameworks using simulated body mass index (BMI), glucose, and systolic blood pressure trajectories, independently isolated shape and magnitude changes, and evaluated model performance across various parameters (e.g., irregularity, missingness). Overall, discrimination based on variation in shape was more challenging than magnitude. Time-series forest-convolutional neural networks (TSF-CNN) and Gramian angular field(GAF)-CNN outperformed other approaches (P < 0.05) with overall area-under-the-curve (AUCs) of 0.93 for both models, and 0.92 and 0.89 for variation in magnitude and shape with up to 50% missing data. Furthermore, in a real-world assessment, the TSF-CNN model predicted T2D with AUCs reaching 0.72 using only BMI trajectories. In conclusion, we performed an extensive evaluation of DL approaches and identified robust modeling frameworks for disease prediction based on longitudinal clinical measurements.

Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension

Pulmonary hypertension is a complex disease with multiple causes, corresponding to phenotypic heterogeneity and variable therapeutic responses. Advancing understanding of pulmonary hypertension pathogenesis is likely to hinge on integrated methods that leverage data from health records, imaging, novel molecular -omics profiling, and other modalities. In this review, we summarize key data sets generated thus far in the field and describe analytical methods that hold promise for deciphering the molecular mechanisms that underpin pulmonary vascular remodeling, including machine learning, network medicine, and functional genetics. We also detail how genetic and subphenotyping approaches enable earlier diagnosis, refined prognostication, and optimized treatment prediction. We propose strategies that identify functionally important molecular pathways, bolstered by findings across multi-omics platforms, which are well-positioned to individualize drug therapy selection and advance precision medicine in this highly morbid disease.

A comprehensive survey on the biomedical signal processing methods for the detection of COVID-19

The novel coronavirus, renamed SARS-CoV-2 and most commonly referred to as COVID-19, has infected nearly 44.83 million people in 224 countries and has been designated SARS-CoV-2. In this study, we used 'web of Science', 'Scopus' and 'goggle scholar' with the keywords of "SARS-CoV-2 detection" or "coronavirus 2019 detection" or "COVID 2019 detection" or "COVID 19 detection" "corona virus techniques for detection of COVID-19", "audio techniques for detection of COVID-19", "speech techniques for detection of COVID-19", for period of 2019-2021. Some COVID-19 instances have an impact on speech production, which suggests that researchers should look for signs of disease detection in speech utilising audio and speech recognition signals from humans to better understand the condition. It is presented in this review that an overview of human audio signals is presented using an AI (Artificial Intelligence) model to diagnose, spread awareness, and monitor COVID-19, employing bio and non-obtrusive signals that communicated human speech and non-speech audio information is presented. Development of accurate and rapid screening techniques that permit testing at a reasonable cost is critical in the current COVID-19 pandemic crisis, according to the World Health Organization. In this context, certain existing investigations have shown potential in the detection of COVID 19 diagnostic signals from relevant auditory noises, which is a promising development. According to authors, it is not a single "perfect" COVID-19 test that is required, but rather a combination of rapid and affordable tests, non-clinic pre-screening tools, and tools from a variety of supply chains and technologies that will allow us to safely return to our normal lives while we await the completion of the hassle free COVID-19 vaccination process for all ages. This review was able to gather information on biomedical signal processing in the detection of speech, coughing sounds, and breathing signals for the purpose of diagnosing and screening the COVID-19 virus.

Implementation of prognostic machine learning algorithms in paediatric chronic respiratory conditions: a scoping review

Machine learning (ML) holds great potential for predicting clinical outcomes in heterogeneous chronic respiratory diseases (CRD) affecting children, where timely individualised treatments offer opportunities for health optimisation. This paper identifies rate-limiting steps in ML prediction model development that impair clinical translation and discusses regulatory, clinical and ethical considerations for ML implementation. A scoping review of ML prediction models in paediatric CRDs was undertaken using the PRISMA extension scoping review guidelines. From 1209 results, 25 articles published between 2013 and 2021 were evaluated for features of a good clinical prediction model using the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines.

Most of the studies were in asthma (80%), with few in cystic fibrosis (12%), bronchiolitis (4%) and childhood wheeze (4%). There were inconsistencies in model reporting and studies were limited by a lack of validation, and absence of equations or code for replication. Clinician involvement during ML model development is essential and diversity, equity and inclusion should be assessed at each step of the ML pipeline to ensure algorithms do not promote or amplify health disparities among marginalised groups. As ML prediction studies become more frequent, it is important that models are rigorously developed using published guidelines and take account of regulatory frameworks which depend on model complexity, patient safety, accountability and liability.

Long-COVID diagnosis: From diagnostic to advanced AI-driven models

SARS-COV 2 is recognized to be responsible for a multi-organ syndrome. In most patients, symptoms are mild. However, in certain subjects, COVID-19 tends to progress more severely. Most of the patients infected with SARS-COV2 fully recovered within some weeks. In a considerable number of patients, like many other viral infections, various long-lasting symptoms have been described, now defined as "long COVID-19 syndrome". Given the high number of contagious over the world, it is necessary to understand and comprehend this emerging pathology to enable early diagnosis and improve patents outcomes. In this scenario, AI-based models can be applied in long-COVID-19 patients to assist clinicians and at the same time, to reduce the considerable impact on the care and rehabilitation unit. The purpose of this manuscript is to review different aspects of long-COVID-19 syndrome from clinical presentation to diagnosis, highlighting the considerable impact that AI can have.

Applications of artificial intelligence in common pulmonary diseases

Artificial intelligence (AI) is a branch of computer science where machines are trained to imitate human-level intelligence and perform well-defined tasks. AI can provide accurate results as well as analyze vast amounts of data that cannot be analyzed via conventional statistical methods. AI has been utilized in pulmonary medicine for almost two decades and its utilization continues to expand. AI can help in making diagnoses and predicting outcomes in pulmonary diseases based on clinical data, chest imaging, lung pathology, and pulmonary function testing. AI-based applications enable physicians to use enormous amounts of data and improve their precision in the treatment of pulmonary diseases. Given the growing role of AI in pulmonary medicine, it is important for practitioners caring for patients with pulmonary diseases to understand how AI can work in order to implement it into clinical practices and improve patient care. The goal of this mini-review is to discuss the use of AI in pulmonary medicine and imaging in cases of obstructive lung disease, interstitial lung disease, infections, nodules, and lung cancer.

An Overview of Medical Electronic Hardware Security and Emerging Solutions

Electronic healthcare technology is widespread around the world and creates massive potential to improve clinical outcomes and transform care delivery. However, there are increasing concerns with respect to the cyber vulnerabilities of medical tools, malicious medical errors, and security attacks on healthcare data and devices. Increased connectivity to existing computer networks has exposed the medical devices/systems and their communicating data to new cybersecurity vulnerabilities. Adversaries leverage the state-of-the-art technologies, in particular artificial intelligence and computer vision-based techniques, in order to launch stronger and more detrimental attacks on the medical targets. The medical domain is an attractive area for cybercrimes for two fundamental reasons: (a) it is rich resource of valuable and sensitive data; and (b) its protection and defensive mechanisms are weak and ineffective. The attacks aim to steal health information from the patients, manipulate the medical information and queries, maliciously change the medical diagnosis, decisions, and prescriptions, etc. A successful attack in the medical domain causes serious damage to the patient’s health and even death. Therefore, cybersecurity is critical to patient safety and every aspect of the medical domain, while it has not been studied sufficiently. To tackle this problem, new human- and computer-based countermeasures are researched and proposed for medical attacks using the most effective software and hardware technologies, such as artificial intelligence and computer vision. This review provides insights to the novel and existing solutions in the literature that mitigate cyber risks, errors, damage, and threats in the medical domain. We have performed a scoping review analyzing the four major elements in this area (in order from a medical perspective): (1) medical errors; (2) security weaknesses of medical devices at software- and hardware-level; (3) artificial intelligence and/or computer vision in medical applications; and (4) cyber attacks and defenses in the medical domain. Meanwhile, artificial intelligence and computer vision are key topics in this review and their usage in all these four elements are discussed. The review outcome delivers the solutions through building and evaluating the connections among these elements in order to serve as a beneficial guideline for medical electronic hardware security.

From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema

Empyema, a severe complication of pneumonia, trauma, and surgery is characterized by fibrinopurulent effusions and loculations that can result in lung restriction and resistance to drainage. For decades, efforts have been focused on finding a universal treatment that could be applied to all patients with practice recommendations varying between intrapleural fibrinolytic therapy (IPFT) and surgical drainage. However, despite medical advances, the incidence of empyema has increased, suggesting a gap in our understanding of the pathophysiology of this disease and insufficient crosstalk between clinical practice and preclinical research, which slows the development of innovative, personalized therapies. The recent trend towards less invasive treatments in advanced stage empyema opens new opportunities for pharmacological interventions. Its remarkable efficacy in pediatric empyema makes IPFT the first line treatment. Unfortunately, treatment approaches used in pediatrics cannot be extrapolated to empyema in adults, where there is a high level of failure in IPFT when treating advanced stage disease. The risk of bleeding complications and lack of effective low dose IPFT for patients with contraindications to surgery (up to 30%) promote a debate regarding the choice of fibrinolysin, its dosage and schedule. These challenges, which together with a lack of point of care diagnostics to personalize treatment of empyema, contribute to high (up to 20%) mortality in empyema in adults and should be addressed preclinically using validated animal models. Modern preclinical studies are delivering innovative solutions for evaluation and treatment of empyema in clinical practice: low dose, targeted treatments, novel biomarkers to predict IPFT success or failure, novel delivery methods such as encapsulating fibrinolysin in echogenic liposomal carriers to increase the half-life of plasminogen activator. Translational research focused on understanding the pathophysiological mechanisms that control 1) the transition from acute to advanced-stage, chronic empyema, and 2) differences in outcomes of IPFT between pediatric and adult patients, will identify new molecular targets in empyema. We believe that seamless bidirectional communication between those working at the bedside and the bench would result in novel personalized approaches to improve pharmacological treatment outcomes, thus widening the window for use of IPFT in adult patients with advanced stage empyema.

Machine Learning Approaches for Predicting Acute Respiratory Failure, Ventilator Dependence, and Mortality in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and contributes to high morbidity worldwide. Patients with COPD have a higher risk for acute respiratory failure, ventilator dependence, and mortality after hospitalization compared with the general population. Accurate and early risk detection will provide more information for early management and better decision making. This study aimed to build prediction models using patients’ characteristics, laboratory data, and comorbidities for early detection of acute respiratory failure, ventilator dependence, and mortality in patients with COPD after hospitalization. We retrospectively collected the electronic medical records of 5061 patients with COPD in three hospitals of the Chi Mei Medical Group, Taiwan. After data cleaning, we built three prediction models for acute respiratory failure, ventilator dependence, and mortality using seven machine learning algorithms. Based on the AUC value, the best model for mortality was built by the XGBoost algorithm (AUC = 0.817), the best model for acute respiratory failure was built by random forest algorithm (AUC = 0.804), while the best model for ventilator dependence was built by LightGBM algorithm (AUC = 0.809). A web service application was implemented with the best models and integrated into the existing hospital information system for physician’s trials and evaluations. Our machine learning models exhibit excellent predictive quality and can therefore provide physicians with a useful decision-making reference for the adverse prognosis of COPD patients.

Digital Transformation and Artificial Intelligence Applied to Business: Legal Regulations, Economic Impact and Perspective

Digital transformation can be defined as the integration of new technologies into all areas of a company. This technological integration will ultimately imply a need to transform traditional business models. Similarly, artificial intelligence has been one of the most disruptive technologies of recent decades, with a high potential impact on business and people. Cognitive approaches that simulate both human behavior and thinking are leading to advanced analytical models that help companies to boost sales and customer engagement, improve their operational efficiency, improve their services and, in short, generate new relevant information from data. These decision-making models are based on descriptive, predictive and prescriptive analytics. This necessitates the existence of a legal framework that regulates all digital changes with uniformity between countries and helps a proper digital transformation process under a clear regulation. On the other hand, it is essential that this digital disruption is not slowed down by the regulatory framework. This work will demonstrate that AI and digital transformation will be an intrinsic part of many applications and will therefore be universally deployed. However, this implementation will have to be done under common regulations and in line with the new reality.

Requirement of artificial intelligence technology awareness for thoracic surgeons

Background

We have recently witnessed incredible interest in computer-based, internet web-dependent mechanisms and artificial intelligence (AI)-dependent technique emergence in our day-to-day lives. In the recent era of COVID-19 pandemic, this nonhuman, machine-based technology has gained a lot of momentum.

Main body of the abstract

The supercomputers and robotics with AI technology have shown the potential to equal or even surpass human experts' accuracy in some tasks in the future. Artificial intelligence (AI) is prompting massive data interweaving with elements from many digital sources such as medical imaging sorting, electronic health records, and transforming healthcare delivery. But in thoracic surgical and our counterpart pulmonary medical field, AI's main applications are still for interpretation of thoracic imaging, lung histopathological slide evaluation, physiological data interpretation, and biosignal testing only. The query arises whether AI-enabled technology-based or autonomous robots could ever do or provide better thoracic surgical procedures than current surgeons but it seems like an impossibility now.

Short conclusion

This review article aims to provide information pertinent to the use of AI to thoracic surgical specialists. In this review article, we described AI and related terminologies, current utilisation, challenges, potential, and current need for awareness of this technology.

A comprehensive review of imaging findings in COVID-19 - status in early 2021

Medical imaging methods are assuming a greater role in the workup of patients with COVID-19, mainly in relation to the primary manifestation of pulmonary disease and the tissue distribution of the angiotensin-converting-enzyme 2 (ACE 2) receptor. However, the field is so new that no consensus view has emerged guiding clinical decisions to employ imaging procedures such as radiography, computer tomography (CT), positron emission tomography (PET), and magnetic resonance imaging, and in what measure the risk of exposure of staff to possible infection could be justified by the knowledge gained. The insensitivity of current RT-PCR methods for positive diagnosis is part of the rationale for resorting to imaging procedures. While CT is more sensitive than genetic testing in hospitalized patients, positive findings of ground glass opacities depend on the disease stage. There is sparse reporting on PET/CT with [18F]-FDG in COVID-19, but available results are congruent with the earlier literature on viral pneumonias. There is a high incidence of cerebral findings in COVID-19, and likewise evidence of gastrointestinal involvement. Artificial intelligence, notably machine learning is emerging as an effective method for diagnostic image analysis, with performance in the discriminative diagnosis of diagnosis of COVID-19 pneumonia comparable to that of human practitioners.

Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases

Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.

Using Artificial Intelligence in Fungal Lung Disease: CPA CT Imaging as an Example

This positioning paper aims to discuss current challenges and opportunities for artificial intelligence (AI) in fungal lung disease, with a focus on chronic pulmonary aspergillosis and some supporting proof-of-concept results using lung imaging. Given the high uncertainty in fungal infection diagnosis and analyzing treatment response, AI could potentially have an impactful role; however, developing imaging-based machine learning raises several specific challenges. We discuss recommendations to engage the medical community in essential first steps towards fungal infection AI with gathering dedicated imaging registries, linking with non-imaging data and harmonizing image-finding annotations.

Pulmonary Hypertension in Association with Lung Disease: Quantitative CT and Artificial Intelligence to the Rescue? State-of-the-Art Review

Accurate phenotyping of patients with pulmonary hypertension (PH) is an integral part of informing disease classification, treatment, and prognosis. The impact of lung disease on PH outcomes and response to treatment remains a challenging area with limited progress. Imaging with computed tomography (CT) plays an important role in patients with suspected PH when assessing for parenchymal lung disease, however, current assessments are limited by their semi-qualitative nature. Quantitative chest-CT (QCT) allows numerical quantification of lung parenchymal disease beyond subjective visual assessment. This has facilitated advances in radiological assessment and clinical correlation of a range of lung diseases including emphysema, interstitial lung disease, and coronavirus disease 2019 (COVID-19). Artificial Intelligence approaches have the potential to facilitate rapid quantitative assessments. Benefits of cross-sectional imaging include ease and speed of scan acquisition, repeatability and the potential for novel insights beyond visual assessment alone. Potential clinical benefits include improved phenotyping and prediction of treatment response and survival. Artificial intelligence approaches also have the potential to aid more focused study of pulmonary arterial hypertension (PAH) therapies by identifying more homogeneous subgroups of patients with lung disease. This state-of-the-art review summarizes recent QCT developments and potential applications in patients with PH with a focus on lung disease.

Applications of Artificial Intelligence (AI) for cardiology during COVID-19 pandemic

Background and aims

Artificial Intelligence (AI) shows extensive capabilities to impact different healthcare areas during the COVID-19 pandemic positively. This paper tries to assess the capabilities of AI in the field of cardiology during the COVID-19 pandemic. This technology is useful to provide advanced technology-based treatment in cardiology as it can help analyse and measure the functioning of the human heart.

Methods

We have studied a good number of research papers on Artificial Intelligence on cardiology during the COVID-19 pandemic to identify its significant benefits, applications, and future scope. AI uses artificial neuronal networks (ANN) to predict. In cardiology, it is used to predict the survival of a COVID-19 patient from heart failure.

Results

AI involves complex algorithms for predicting somewhat successful diagnosis and treatments. This technology uses different techniques, such as cognitive computing, deep learning, and machine learning. It is incorporated to make a decision and resolve complex challenges. It can focus on a large number of diseases, their causes, interactions, and prevention during the COVID-19 pandemic. This paper introduces AI-based care and studies its need in the field of cardiology. Finally, eleven major applications of AI in cardiology during the COVID-19 pandemic are identified and discussed.

Conclusions

Cardiovascular diseases are one of the major causes of death in human beings, and it is increasing for the last few years. Cardiology patients' treatment is expensive, so this technology is introduced to provide a new pathway and visualise cardiac anomalies. AI is used to identify novel drug therapies and improve the efficiency of a physician. It is precise to predict the outcome of the COVID-19 patient from cardiac-based algorithms. Artificial Intelligence is becoming a popular feature of various engineering and healthcare sectors, is thought for providing a sustainable treatment platform. During the COVID-19 pandemic, this technology digitally controls some processes of treatments.